[CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma].

[CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma]. Praxis (Bern 1994). 2018;107(21):1129-1135 Authors: Platzer S, Fehr T, Latshang T Abstract CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma Abstract. The challenging therapy of severe uncontrollable bronchial asthma aims primarily at sufficient symptom control and the minimization of the exacerbation rate. If, despite extended drug therapy, symptom control is very difficult to achieve, biologics should preferably be used instead of corticosteroid therapy. The aim of this article is to point out these different asthma therapy pathways and to describe diagnostic criteria as well as practical experiences through application in patients. PMID: 30326819 [PubMed - in process]
Source: Praxis - Category: General Medicine Authors: Tags: Praxis (Bern 1994) Source Type: research